AstraZeneca targets Rhythm with $10bn offer

A margin of roughly 13% separates Rhythm's market close from the bid value, creating potential for negotiation if discussions proceed, but it also demonstrates the possibility that no agreement might be reached. The publication of the bid will likely spark interest in other midsized biotech firms in obesity and rare diseases, as big pharmaceutical groups show significant interest in these fields. For AstraZeneca, a bid this size is not expected to significantly affect its share price, yet it suggests a strategy of buying expansion to achieve its 2030 revenue objective. Chinese drugmakers who have licensed obesity assets to Western companies may also gain attention within this acquisition trend.

AstraZeneca's move represents a bid to occupy a specific niche within the expanding obesity treatment sector, and it is spending heavily for that position.

Key elements of the report:

• An offer valued at about $10 billion, or $124 per share, was made for Rhythm Pharmaceuticals in the prior month, according to individuals familiar with the matter.
• Rhythm's stock surged 28% to roughly $110, bringing the firm's valuation to around $7.6 billion.
• The company possesses therapies for specific obesity types, such as an authorised treatment for acquired hypothalamic obesity.
• Acquiring Rhythm would enhance AstraZeneca's obesity offering and rare disease segment, the latter built up through the Alexion purchase.
• The drugmaker has a target of $80 billion in yearly sales by 2030, compared with around $59 billion last year.

The Wall Street Journal, relying on individuals familiar with the situation, reported that AstraZeneca has made a roughly $10 billion bid for Rhythm Pharmaceuticals, deepening the UK company's drive into obesity and rare disease medications.

The bid, placed at $124 per share for the US company, came the previous month, with prior interest having been registered. Rhythm's stock was near $95 on Wednesday, suggesting a 30% premium roughly. By closure, the stock had climbed 28% to just above $110, placing a valuation of around $7.6 billion on the company. The report lacked comments from both parties, and the proposition is yet to receive confirmation.

The roughly 13% difference between the market close and the offer value implies investors perceive a degree of doubt regarding finalisation at the stated price.

Therapies from Rhythm target rare obesity types connected to the MC4R pathway, a system that controls appetite signals. A breakdown of this pathway can cause intense, chronic hunger resulting in serious obesity. The firm's portfolio features a drug approved for the uncommon condition of acquired hypothalamic obesity.

The deal suits AstraZeneca for two reasons. It is constructing an obesity product line to establish itself in a swiftly expanding drug market. Among its GLP-1 assets is a therapy from China's Eccogene, acquired for around $185 million in 2023, and a January acquisition of obesity and diabetes programs from another Chinese company, CSPC Pharmaceuticals, for $1.2 billion up front.

Additionally, Rhythm would enrich AstraZeneca's rare disease collection, which reached a leading status thanks to the 2021, $39 billion buyout of Alexion.

The acquisition strategy matches a wider plan. AstraZeneca, with a market valuation of almost $300 billion and a strong reputation in oncology under CEO Pascal Soriot, aims for yearly revenue of $80 billion by 2030, an increase from roughly $59 billion in the prior year. Industry analysts point out that acquisitions will be required to fill its product pipeline to accomplish this aim.

An agreement of about $10 billion would be relatively small-scale for AstraZeneca, yet it would be significant for a focused obesity firm and highlights the trend of major pharmaceutical companies employing M&A to drive expansion.